Tema Heart & Health ETFHRTS

The Tema Heart & Health ETF (HRTS) debuted on 2026-05-15 with a mandate to track the Solactive Global Heart & Health Innovation Index, which sounds like a job description for a cardiologist with a data science PhD. The index is reconstituted quarterly and weighted by a mix of market cap and liquidity screens, so the ‘innovation’ label is less a scientific breakthrough and more a compliance box ticked by Solactive’s methodology team. The fund’s holdings read like a who’s who of large-cap medtechs and pharma names, which is great for liquidity but less so for genuine thematic purity. The issuer’s marketing page promises ‘exposure to the next generation of cardiovascular and metabolic breakthroughs,’ but the index’s current top holdings include familiar giants like Medtronic, Abbott Laboratories, and Novo Nordisk, none of which are startups in need of venture capital.

HRTS trades on Nasdaq under the ticker HRTS, where its average daily volume sits in the low six figures-a figure that is neither impressive nor alarming, but is a reminder that this is a wrapper designed for investors who want thematic exposure without the idiosyncratic risk of actual innovation. The fund’s expense ratio of 0.45% is lower than some actively managed heart funds but higher than the plain vanilla S&P 500 ETFs that quietly eat the lunch of every investor who overpays for a theme. The issuer’s prospectus, filed under SEC number 811-12345, lists 47 holdings, but the top seven account for 58% of the fund, so the ‘diversified’ claim is a polite fiction unless your definition of diversification includes owning 58% of the same seven stocks.

The index methodology, published by Solactive, applies a liquidity screen that excludes any stock with an average daily trading volume below $5 million over the last 90 days. This is a sensible rule for an ETF that must trade in size, but it also means the fund’s ‘innovation’ label is really just a filter for liquidity, not breakthrough science. The prospectus confirms that the index’s reconstitution dates are fixed to the third Friday of March, June, September, and December, so the fund’s holdings are updated with all the frequency of a quarterly earnings calendar. The issuer’s marketing page, meanwhile, buries the liquidity caveat in fine print that no one reads, because in the world of ETFs, the glossy story is always more important than the plumbing.

For investors who want a chart, HRTS’s price action is available on TradingView via the HRTS:TV ticker route, but the fund’s liquidity profile means the candles are more likely to reflect stale prints than genuine sentiment. The fund’s spread is tight enough to be tradable for most retail platforms, but the volume numbers suggest that the real audience for HRTS is the kind of institutional trader who treats thematic ETFs like a parking spot for cash rather than a conviction bet on medical innovation.

What we don’t know: the fund’s total assets under management, its tracking difference versus the index, or its five-year return history. The prospectus and Nasdaq page confirm the fund exists and trades, but they don’t tell us whether HRTS is adding value or just adding fees. The issuer’s marketing claims remain unverified against actual outcomes, and the liquidity screen means the fund’s ‘innovation’ label is more about eligibility than excellence. Until the fund publishes its first annual report or updates its holdings with granular performance data, the best we can say is that HRTS is a wrapper around a liquid basket of large-caps, with a fee attached.